Quality Defects and Product Recalls: Classification, Timelines and the Mock Recall You Have Not Run

A recall is the moment a quality system is tested in public. Under the EU GMP framework, how quickly a suspected defect is assessed, classified and escalated determines whether patients are protected and whether the company keeps its credibility with the regulator. The time to find out your procedure does not work is not during a live recall.

From complaint to defect report

Chapter 8 of the EU GMP Guide (complaints, quality defects and product recalls) expects written procedures covering how a defect is described, risk-assessed and investigated for root cause, how corrective and preventive actions are set, and when the competent authority must be informed. The revised chapter aligns with Directive 2003/94/EC on when a defect or complaint should be reported, and it expects Qualified Persons to be told promptly of investigations and of the actions taken to reduce risk.

In practice, the weak point is rarely the investigation itself. It is the first 24 hours: who decides that a complaint is a potential defect, who tells the QP, and who contacts the Marketing Authorisation Holder when manufacturing, release and distribution sit with different companies.

Risk-based classification and response times

The EMA/HMA procedure for managing classification of reports of suspected quality defects uses a risk-based approach with three levels, each with a target for action by the authorities:

  • High risk: defects that are potentially life-threatening or could cause serious risk to health, such as a wrong product or strength, or microbial contamination of a sterile product. Target: 3 working days, shortened to 1 working day where there is a major public health impact.
  • Moderate risk: defects that could cause illness or mistreatment with potentially non-serious medical consequences, such as mislabelling. Target: 5 working days.
  • Low risk: defects unlikely to pose a significant hazard to health. Target: 10 working days, on an optional basis.

Where a defect justifies a recall, the Rapid Alert system distinguishes Class I (life-threatening, reaching patient or user level), Class II (potential for illness or mistreatment, reaching pharmacy or retail level) and Class III (low hazard, wholesaler level, not notified through the Rapid Alert system). The depth of the recall follows the class.

Recall readiness: what inspectors look for

Chapter 8 requires recall procedures that can be started promptly and at any time. It also expects the decision to be risk-based, balancing patient safety against continued access where few alternatives exist, and to be taken in consultation with the authorities for critical medicines. Mock recalls should be considered for both office-hours and out-of-office-hours scenarios, with the reasoning documented either way.

Common gaps we see in the market include:

  • Out-of-hours contact lists that are out of date or held by one person.
  • Quality agreements that do not set a notification time between manufacturer, QP and MAH.
  • Distribution records that cannot show quickly which wholesalers and pharmacies received a given batch.
  • CAPA closed on paperwork, without a check that it worked.

How PQRA helps

PQRA supports pharmaceutical companies in Greece and the EU with Quality Assurance and regulatory strategy: drafting and testing complaint, defect and recall procedures, designing and facilitating mock recalls, reviewing quality agreements, and preparing teams for GMP and GDP inspections. Our regulatory affairs team also helps coordinate communication with the national competent authority when a defect becomes a market action.

Contact PQRA to review your recall readiness before you need it.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *